Martin Nutraceuticals Inc. Finalizing Agreement for Marketing and Distribution Rights for CGY-25(R) in Canada and the United States.RENO, Nev. -- Martin Nutraceuticals Inc. (PINKSHEETS: MNCL MNCL Maintenance Non-Computing (Module) Load ) today announced the finalizing of an agreement for distribution rights of CGY-25[R] with NormallyPharma for Canada, and is in final negotiations for the distribution rights for the United States. CGY-25 is for the treatment of male testosterone deficiency also commonly referred to as andropause andropause /an·dro·pause/ (an´dro-pawz) a variable complex of symptoms, including decreased Leydig cell numbers and androgen production, occurring in men after middle age, purported to be analogous to menopause in women. . CGY-25 stimulates the secretion of a male sex hormone sex hormone n. Any of various steroid hormones, such as estrogen and androgen, affecting the growth or function of the reproductive organs and the development of secondary sex characteristics. in the Leydig cells Leydig cells Cells that make up the endocrine tissue of the testis and produce testosterone. They are named for Franz von Leydig (1821–1908), the German professor of anatomy who first identified them. for the natural treatment of testosterone deficiency. It is estimated that testosterone deficiency or andropause directly affects more than 11 million men in North America and is believed to have a correlation with Erectile Dysfunction Erectile Dysfunction Definition Erectile dysfunction (ED), formerly known as impotence, is the inability to achieve or maintain an erection long enough to engage in sexual intercourse. (ED), which affects upwards of 30 million North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. men. Treatment of (ED) and other related erectile deficiency's is a $3.5+B business today via prescribed drugs, most notably, Viagra, Cialis and Levitra. Despite the dominance of these products, several opportunities exist for a successful market entry. According to the market research firm ImpactRx, which tracks the habits of a panel of high prescribing physicians and may reflect emerging trends in doctors' offices today. Upon the introduction of a NEW drug (Cialis) for (ED) in 2004, U.S. urologists initiated treatment with Cialis at a rate of more than two-to-one over each of the other oral ED treatments. In fact, the NEW drug, Cialis, represented 56 percent of new treatment initiations by urologists compared to 21 percent for Levitra and 23 percent for Viagra. Testosterone Deficiency is characterized by symptoms of fatigue, negative moods and loss of sex drive. Only 5% of men suffering from testosterone deficiency are being treated in North America today. "Men need to understand that the symptoms of low testosterone are not an irreversible element of the aging process. Testosterone deficiency is a medical condition that can be treated successfully," said Dr. Alvaro Morales, Professor of Urology urology Medical specialty dealing with the urinary system and male reproductive organs. It traces its origin to medieval lithologists, itinerant healers who specialized in surgical removal of bladder stones. at Queen's University. CGY-25 has demonstrated improvements in mood and libido and has restored testosterone to normal physiological levels and further studies have shown that CGY-25 properties have shown to help generate the liver. This product and it's properties are in direct contrast to the many side affects the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. warns about on other ED type drugs including negative side affects to the liver. Also, these other popular drugs make no claims regarding the enhancement of mood, libido or testosterone restoration giving CGY-25 a distinct advantage throughout this sector. "This agreement not only strengthens the competitive position of CGY-25 (MARTINEX) in North America, but gives Martin Nutraceuticals the ability to penetrate a multi-billion dollar market segment," states Harvey Panesar, President of Martin Nutraceuticals Inc. "We also maintain the integrity of our corporate objective of finding the best possible, all natural products, that help individuals in creating a better lifestyle and we believe that CGY-25 will do that." CGY-25[R] will be available shortly through the Martin Nutraceuticals Inc. website at: www.martinnutra.com. THE CGY-25[R] ADVANTAGE CGY-25 is a Twice-daily Supplement that provides delivery that stimulates the secretion of male sex hormone in the Leydig cells therefore increasing the testosterone for 24 hours Adv. 1. for 24 hours - without stopping; "she worked around the clock" around the clock, round the clock following application. It provides significant advantages compared to other therapies currently available due to its effectiveness without side effects Side effects Effects of a proposed project on other parts of the firm. . The majority of products within this sector are comprised of a variety of chemicals which is the primary reason for their lengthy list of side affects. About Martin Nutraceuticals Inc.: Martin Nutraceuticals Inc. is a company focused on providing a better health and lifestyle through natural products. Martin Nutraceuticals flagship products include Arthrizyme(TM) for general joint pain and Oxygenol(TM) for anti-oxidation and Maximum Slim(TM) for weight control. Arthrizyme(TM) is a unique blend of systemic enzymes proven to rapidly reduce inflammation in joints and muscles. Arthrizyme(TM) is not limited to anti-inflammatory effects; it also assists the body in the healing process by breaking down fibrin fibrin: see blood clotting. in joints and muscles. Arthrizyme(TM) differs from all other natural arthritis remedies and was designed to work for all types of arthritis and in all joints of the body. Arthrizyme(TM) is fast acting, usually improving symptoms within the first few days. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The risks and uncertainties that may affect the operations, performance development and results of the Company's business include, but are not limited to, fluctuations in financial results, availability and customer acceptance of our products and services, the impact of competitive products, services and pricing, general market trends and conditions. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion